Founded in 2000 in Barcelona, Spain, Oryzon Genomics, S.A. (ISIN Code: ES0167733015) (“Oryzon”) is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. The company leverages epigenetics to discover and develop innovative therapeutics for diseases with a strong unmet medical need, with a focus on CNS, oncology and hematology.
The company has a broad and advanced portfolio, with two compounds in clinical trials: vafidemstat (also known as ORY-2001), a CNS optimized LSD1 inhibitor advancing as a Phase III-ready asset for neurological and psychiatric disorders, and iadademstat (also known as ORY-1001), a highly potent and selective LSD1 inhibitor in Phase Ib and II trials in oncology and hematology, which has been granted orphan-drug status by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Oryzon is supported by an experienced management team, an international Board of Directors, and world-renowned clinical, regulatory and industry experts.
Oryzon has offices in Spain and the United States.
